ID   IVR02
AC   CVCL_E5FU
SY   In Vivo Resistant 02
RX   PubMed=35918200;
CC   Population: Caucasian.
CC   Characteristics: Female nude mice were injected IP with the parent cell line. Once tumours were established the mice were treated with carboplatin. This cell line was establishe from one of these in-vivo established resistant tumor cells (PubMed=35918200).
CC   Selected for resistance to: ChEBI; CHEBI_31355; Carboplatin (CBP; Paraplatin).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Leu130Val (c.388C>G); ClinVar=VCV000458543; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transduction; Gene=FPbase; R9NL8; eGFP (Note=Enhanced GFP).
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P08659; Firefly luciferase.
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_E5FK ! OVCAR4-Luc
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=35918200; DOI=10.1016/j.ygyno.2022.07.027;
RA   Hoare J.I., Hockings H., Saxena J., Silva V.L., Haughey M.J., Wood G.E.,
RA   Nicolini F., Mirza H., McNeish I.A., Huang W.-N., Maniati E.,
RA   Graham T.A., Lockley M.;
RT   "A novel cell line panel reveals non-genetic mediators of platinum
RT   resistance and phenotypic diversity in high grade serous ovarian
RT   cancer.";
RL   Gynecol. Oncol. 167:96-106(2022).
//